EPIODYNE, INC.

SAN FRANCISCO, CA · Founded 2016 · Biotech · Private

Oral mu-opioid receptor partial agonist small molecules for pain management, with lead candidate EPD2520 designed to reduce respiratory depression and addiction liability compared to traditional opioi

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · epiodyne.com

Sector: Biotech
Headquarters: SAN FRANCISCO, CA
Founded: 2016
Latest Form D: $8M, Apr 2019
Total capital: $17.1M

Federal grants: $2.8M; 3 awards · 2018–2023; Rank in peer group#372 of 514
Private capital raised: $14.3M; 3 Form D · last Apr 2019; 90 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 3; 9 pending · first 2022; Rank in peer group#109 of 514

Capital timeline

Latest events

Mar 2023Federal grantHealth and Human S · Phase II · Development of an oral analgesic with reduced liabilities$1.5M
Apr 2022Federal grantHealth and Human S · Phase II · Development of an oral analgesic with reduced liabilities$1M
Apr 2019Private capital raisedForm D · SEC · 3rd filing$8M
Aug 2018Federal grantHealth and Human S · Phase I · Structure-based Optimization of Novel Analgesics without Reinforcing Liabilities$300K
Nov 2017Private capital raisedForm D · SEC · 2nd filing$5.8M
Jun 2016Private capital raisedForm D · SEC · 1st filing$500K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grantsBelow median
Granted patents#109 · top 21%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings

Alex TkachenkoExecutive Officer, DirectorNamed in SEC Form D filings
Brian ShoichetDirectorNamed in SEC Form D filings
Brook ByersDirectorNamed in SEC Form D filings
Douglas CrawfordExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

USPTO · 3 granted of 12

Dec 17, 2024GrantedOpioid Receptor ModulatorsUSPTOUS 12,168,648
Apr 25, 2023GrantedOpioid Receptor ModulatorsUSPTOUS 11,634,396
Jun 7, 2022GrantedOpioid Receptor Modulators And Products And Methods Related TheretoUSPTOUS 11,352,316

Show all 12 patent records

Opioid Receptor ModulatorsDec 17, 2024 · US 12,168,648Granted
Opioid Receptor ModulatorsApr 25, 2023 · US 11,634,396Granted
Opioid Receptor Modulators And Products And Methods Related TheretoJun 7, 2022 · US 11,352,316Granted
Opioid Receptor Modulators And Products And Methods Related TheretoMay 20, 2021 · Application 17045152Pending
Opioid Receptor ModulatorsApplication 63171008Pending
Opioid Receptor ModulatorsApplication PCTUS2022023546Pending
Opioid Receptor Modulators And Products And Methods Related TheretoApplication 16691377Pending
Opioid Receptor Modulators And Products And Methods Related TheretoApplication PCTUS2019025910Pending
Opioid Receptor Modulators And Products And Methods Related TheretoApplication 16375811Pending
Opioid Receptor Modulators And Products And Methods Related TheretoApplication 62792754Pending
Opioid Receptor ModulatorsApplication 63318486Pending
Opioid Receptor Modulators And Products And Methods Related TheretoApplication 62652819Pending

FLUGEN, INC.Similar federal contract value in Biotech · null in contracts
CAPRICOR, INC.Similar federal contract value in Biotech · null in contracts
Kalyra Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
JANGOBIO, LLCSimilar federal contract value in Biotech · null in contracts
GEMNEO BIOSCIENCE, INC.Similar federal contract value in Biotech · null in contracts
TriAltus Bioscience, LLCSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.